CARE- Feline HCM Stage C
Principle Investigator
Description
The objective of this study is to evaluate the safety and efficacy of this investigational product in cats diagnosed with hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM) following their first onset of congestive heart failure (CHF). Specifically, the study aims to determine whether treatment with the investigational product can delay the progression of cardiac disease, reduce the occurrence of cardiac-related morbidity, and extend the time to cardiac-related mortality. By assessing clinical outcomes over time, this research seeks to better understand the potential role of the investigational product in improving both the quality and duration of life for cats affected by these serious cardiac conditions. This is a double-blind, placebo-controlled study of a once-daily oral liquid investigational medication administered by the cat owner, with the goal of achieving approval by FDA.
Testing Requirements
Ability to administer once daily liquid oral medication
Enrollment Start
06/01/2026
Enrollment Finish
06/01/2030
Eligibility
• Diagnosis at screening visit or history of primary cardiomyopathy confirmed by echocardiography
• Diagnosis of a first congestive heart failure episode (ACVIM Stage C) within the last 60 days before screening visit based on clinical symptom(s)
• Age: ≥ 12 months at screening visit
• Body weight ≥ 2.0kg/4.4lbs